Glycosaminoglycans in Neurodegenerative Diseases

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2021 Sep 8

PMID 34495536

Citations 6

Authors

Weihua Jin

Fuming Zhang

Robert J Linhardt

Affiliations

Soon will be listed here.

Abstract

Glycosaminoglycans (GAGs) are linear polysaccharides that consist of alternating disaccharides sequences of uronic acids and/or galactose hexamino sugars most of which are sulfated. GAGs are ubiquitously expressed on the cell surface, in the intracellular milieu and in the extracellular matrix of all animal cells. Thus, GAGs exhibit many essential roles in a variety of physiological and pathological processes. The targets of GAGs are GAG-binding proteins and related proteins that are of significant interest to both the academic community and in the pharmaceutical industry. In this review, the structures of GAGs, their binding proteins, and analogs are presented that further the development of GAGs and their analogs for the treatment of neurodegenerative diseases agents.

Citing Articles

Serum Amyloid A Binding to Glycosaminoglycans is Synergistic with Amyloid Formation: Therapeutic Targeting in the Inflammation-linked Amyloidosis.

Jayaraman S, Urdaneta A, Fandrich M, Gursky O J Mol Biol. 2025; 437(8):169007.

PMID: 39954777 PMC: 11903164. DOI: 10.1016/j.jmb.2025.169007.

High-throughput glycosaminoglycan extraction and UHPLC-MS/MS quantification in human biofluids.

Volpi N, Galeotti F, Gatto F Nat Protoc. 2024; .

PMID: 39543382 DOI: 10.1038/s41596-024-01078-9.

Heparan sulfate proteoglycan in Alzheimer's disease: aberrant expression and functions in molecular pathways related to amyloid-β metabolism.

McMillan I, Li J, Wang L Am J Physiol Cell Physiol. 2023; 324(4):C893-C909.

PMID: 36878848 PMC: 10069967. DOI: 10.1152/ajpcell.00247.2022.

Introduction to the Complexity of Cell Surface and Tissue Matrix Glycoconjugates.

Bhavanandan V, Gowda D Adv Neurobiol. 2022; 29:1-39.

PMID: 36255670 DOI: 10.1007/978-3-031-12390-0_1.

Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease.

Caird R, Williamson M, Yusuf A, Gogoi D, Casey M, McElvaney N Int J Mol Sci. 2022; 23(12).

PMID: 35742845 PMC: 9224208. DOI: 10.3390/ijms23126400.

References

Naini S, Soussi-Yanicostas N . Heparan Sulfate as a Therapeutic Target in Tauopathies: Insights From Zebrafish. Front Cell Dev Biol. 2019; 6:163. PMC: 6306439. DOI: 10.3389/fcell.2018.00163. View

Ancsin J . Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid. 2003; 10(2):67-79. DOI: 10.3109/13506120309041728. View

Appel S, Smith R, Le W . Immune-mediated cell death in neurodegenerative disease. Adv Neurol. 1996; 69:153-9. View

Arai H, Kashiwagi S, Nagasaka Y, Uchida K, Hoshii Y, Nakamura K . Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans. Arch Biochem Biophys. 1999; 367(1):1-8. DOI: 10.1006/abbi.1999.1222. View

Avram S, Shaposhnikov S, Buiu C, Mernea M . Chondroitin sulfate proteoglycans: structure-function relationship with implication in neural development and brain disorders. Biomed Res Int. 2014; 2014:642798. PMC: 4052930. DOI: 10.1155/2014/642798. View

Bame K, DANDA J, Hassall A, Tumova S . Abeta(1-40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimer's disease. J Biol Chem. 1997; 272(27):17005-11. DOI: 10.1074/jbc.272.27.17005. View

Barros C, Franco S, Muller U . Extracellular matrix: functions in the nervous system. Cold Spring Harb Perspect Biol. 2010; 3(1):a005108. PMC: 3003458. DOI: 10.1101/cshperspect.a005108. View

Bejoy J, Song L, Wang Z, Sang Q, Zhou Y, Li Y . Neuroprotective Activities of Heparin, Heparinase III, and Hyaluronic Acid on the A42-Treated Forebrain Spheroids Derived from Human Stem Cells. ACS Biomater Sci Eng. 2018; 4(8):2922-2933. PMC: 6286050. DOI: 10.1021/acsbiomaterials.8b00021. View

Bellucci C, Lilli C, Baroni T, Parnetti L, Sorbi S, Emiliani C . Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease. Mol Med. 2007; 13(9-10):542-50. PMC: 1933258. DOI: 10.2119/2007-00034.Bellucci. View

10.

Ben-Zaken O, Tzaban S, Tal Y, Horonchik L, Esko J, Vlodavsky I . Cellular heparan sulfate participates in the metabolism of prions. J Biol Chem. 2003; 278(41):40041-9. DOI: 10.1074/jbc.M301152200. View

11.

Bergamaschini L, Rossi E, Vergani C, De Simoni M . Alzheimer's disease: another target for heparin therapy. ScientificWorldJournal. 2009; 9:891-908. PMC: 5823143. DOI: 10.1100/tsw.2009.100. View

12.

Bernstein H, Stricker R, Dobrowolny H, Steiner J, Bogerts B, Trubner K . Nardilysin in human brain diseases: both friend and foe. Amino Acids. 2013; 45(2):269-78. DOI: 10.1007/s00726-013-1499-8. View

13.

Bullock S, Fletcher J, Beddington R, WILSON V . Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev. 1998; 12(12):1894-906. PMC: 316906. DOI: 10.1101/gad.12.12.1894. View

14.

Capila I, Linhardt R . Heparin-protein interactions. Angew Chem Int Ed Engl. 2002; 41(3):391-412. DOI: 10.1002/1521-3773(20020201)41:3<390::aid-anie390>3.0.co;2-b. View

15.

Carmen L, Maria V, Morales-Medina J, Vallelunga A, Palmieri B, Iannitti T . Role of proteoglycans and glycosaminoglycans in Duchenne muscular dystrophy. Glycobiology. 2018; 29(2):110-123. DOI: 10.1093/glycob/cwy058. View

16.

Carulli D, Laabs T, Geller H, Fawcett J . Chondroitin sulfate proteoglycans in neural development and regeneration. Curr Opin Neurobiol. 2005; 15(1):116-20. DOI: 10.1016/j.conb.2005.01.014. View

17.

Castillo G, Ngo C, Cummings J, Wight T, Snow A . Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem. 1997; 69(6):2452-65. DOI: 10.1046/j.1471-4159.1997.69062452.x. View

18.

Castillo G, Cummings J, Yang W, JUDGE M, Sheardown M, Rimvall K . Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes. 1998; 47(4):612-20. DOI: 10.2337/diabetes.47.4.612. View

19.

Castillo G, Lukito W, Wight T, Snow A . The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem. 1999; 72(4):1681-7. DOI: 10.1046/j.1471-4159.1999.721681.x. View

20.

CELESIA G . Alzheimer's disease: the proteoglycans hypothesis. Semin Thromb Hemost. 1991; 17 Suppl 2:158-60. View